Skip to main content
. 2021 Dec 16;4(3):254–258. doi: 10.1002/acr2.11380

Figure 1.

Figure 1

Pain reduction between opioid users and nonusers by analysis population. A, Baricitinib 4 mg versus placebo with data from the pooled analysis population (RA‐BEAM, RA‐BUILD, and RA‐BEACON). B, Baricitinib 2 mg versus placebo with data from pooled analysis population (RA‐BUILD and RA‐BEACON). C, Adalimumab 40 mg versus placebo with data from RA‐BEAM.